Meeder Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Meeder Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11	Closed	-$3K	–	2278
2020 Q2	$3K	Sell	11 -312	-97%	-$92.3K	﹤0.01%	1673
2020 Q1	$94K	Buy	323 +166	+106%	+$45.8K	0.01%	731
2019 Q4	$45K	Buy	157 +141	+881%	+$30.6K	﹤0.01%	1046
2019 Q3	$2K	Buy	+16	New	+$2.17K	﹤0.01%	1959
2018 Q3	–	Sell	-4	Closed	-$934	–	1619
2018 Q2	$934	Sell	4 -1	-20%	-$247	﹤0.01%	1512
2018 Q1	$1K	Buy	+5	New	+$997	﹤0.01%	1457
2017 Q2	–	Sell	-23	Closed	-$5K	–	1769
2017 Q1	$5K	Sell	23 -68	-75%	-$10.9K	﹤0.01%	1075
2016 Q4	$13K	Buy	+91	New	+$12.3K	﹤0.01%	711

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Meeder Asset Management's KPTI Position: Q3 2020 in Review

Meeder Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2020, closing a stake of 11 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in KPTI in Q4 2016 and held it in 8 quarters. The position peaked at $94K in Q1 2020. 157 funds tracked by Wall St. Rank hold KPTI as of Q3 2020.

Meeder Asset Management reported no remaining Karyopharm Therapeutics position as of Q3 2020 after selling out during the quarter.
Meeder Asset Management sold 11 Karyopharm Therapeutics shares in Q3 2020, an estimated $3K.
Meeder Asset Management first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Karyopharm Therapeutics position peaked at $94K in Q1 2020.
157 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.